NAMS 19.03 NewAmsterdam Pharma Company N.V.
| Range: | 5.633-26.35 | Vol Avg: | 356248 | Last Div: | 0 | Changes: | 0.57 |
| Beta: | 0 | Cap: | 1.64B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Tue Feb 09 2021 | Empoloyees: | 57 | ||
| CUSIP: | CIK: | 0001936258 | ISIN: | NL00150012L7 | Country: | NL | |
| CEO: | Dr. Michael Harvey Davidson FACC, Facp., M.D. | Website: | https://www.newamsterdampharma.com | ||||
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Stock Details
NAMS 37
Piper Sandler Reiterates Overweight Rating on NewAmsterdam Pharma Co NV (NAMS)
Yasmeen Rahimi·Mon Sep 23 2024
Piper Sandler
NAMS 36
NewAmsterdam Pharma initiated with a Buy at Needham
Serge Belanger·Wed Aug 28 2024
Needham
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow